Hypokalaemia (serum potassium < 3.5 mmol/L)
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
< 2.5 mmol/L, symptoms or ECG changes: emergency department
- No tests in the community: refer to the emergency department for intravenous replacement under continuous ECG monitoring.
- Serum potassium < 2.5 mmol/L, muscle weakness or paralysis, ECG abnormality or arrhythmia, vomiting preventing oral intake.
2.5 to 3.4 mmol/L: tests
Laboratory tests
- Serum electrolytes (repeat serum potassium, serum sodium, chloride)
- Bicarbonate
- Serum magnesium
- Serum creatinine with eGFR
- Plasma glucose
- TSH (if tachycardia or episodes of paralysis)if needednon-French guidelineTachycardia, signs of thyrotoxicosis or episodes of weakness or paralysis: thyrotoxicosis can cause hypokalaemia by shift (thyrotoxic periodic paralysis) [2].
- Serum digoxin (if on digoxin)if needednon-French guidelinePatient treated with digoxin: hypokalaemia promotes arrhythmias on digitalis, and serum digoxin should be measured [2].
Urine tests (spot sample, same day, before any potassium replacement)
- Urinary electrolytes (sodium, potassium)
- Urinary creatinine: urinary potassium:creatinine ratio
- Urinary chloride (if the cause is not found on history and examination)if needednon-French guidelineHypokalaemia whose cause is not explained by the history and examination: in the United States, an American Family Physician review has urinary chloride measured with urinary sodium, potassium and creatinine, as well as renin and aldosterone [3]. In France, urinary chloride has no NABM code: it is not reimbursed [4].
If hypertension: after correction of serum potassium
- Plasma aldosterone and renin, with aldosterone:renin ratio (conditions: see the note)if neededHypokalaemia, spontaneous or on a diuretic, in a hypertensive patient with normal GFR: screening for primary hyperaldosteronism [1,2]. To be done with normal potassium, in the morning, more than 2 hours after getting up, seated for 5 to 15 minutes [5].
- Renin-aldosterone: in the morning, more than 2 h after getting up, seated for 5 to 15 min, with normal serum potassium, on a normal-sodium diet; aldosterone antagonists stopped (see the note).
Do not order
Sources (8)
- Clase CM, Carrero JJ, Ellison DH, et al. ; KDIGO Controversies Conference Participants. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2020;97(1):42-61.
- Kardalas E, Paschou SA, Anagnostis P, Muscogiuri G, Siasos G, Vryonidou A. Hypokalemia: a clinical update. Endocr Connect. 2018;7(4):R135-R146.
- Kim MJ, Valerio C, Knobloch GK. Potassium Disorders: Hypokalemia and Hyperkalemia. Am Fam Physician. 2023;107(1):59-70A.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : sous-chapitre 13-03 (urines) et acte 0327 (digoxine).
- Douillard C, Houillier P, Nussberger J, Girerd X. Consensus SFE/SFHTA/AFCE sur l'hyperaldostéronisme primaire, partie 2 : premières étapes diagnostiques. Version française de : Ann Endocrinol (Paris). 2016;77(3):192-201.
- Adler GK, Stowasser M, Correa RR, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110(9):2453-2495 (erratum 2025;110(11):e3933-e3934).
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit CISPLATINE HIKMA 1 mg/mL, solution à diluer pour perfusion, rubrique 4.8.
- ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit MACROGOL BIOGARAN 10 g, poudre pour solution buvable, rubrique 4.8.